More specifically, in pancreatic cancer, the most commonly reported KRAS mutation is the substitution of valine (V) or aspartic acid (D) for glycine (G) at position 2 in codon 12 (GGT [encoding G] → GTT [encoding V] or GAT [encoding D]) [35]. Here, KRAS is linked to pancreatic neoplasm.